Barclays PLC Madrigal Pharmaceuticals, Inc. Call Options Transaction History

Barclays PLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$193.33 - $291.99 $1.68 Million - $2.54 Million	-8,700 Reduced 96.67%	300 $84,000
Q1 2024 May 15, 2024	BUY	$171.37 - $283.23 $1.54 Million - $2.55 Million	9,000 New	9,000 $2.4 Million
Q1 2023 May 04, 2023	BUY	$231.06 - $307.08 $4.07 Million - $5.4 Million	17,600 New	17,600 $4.26 Million
Q1 2019 May 15, 2019	SELL	$103.48 - $143.84 $2.9 Million - $4.03 Million	-28,000 Reduced 67.47%	13,500 $1.69 Million
Q4 2018 Feb 14, 2019	BUY	$94.77 - $215.54 $1.94 Million - $4.42 Million	20,500 Added 97.62%	41,500 $4.68 Million
Q3 2018 Nov 14, 2018	BUY	$207.3 - $300.31 $3.5 Million - $5.08 Million	16,900 Added 412.2%	21,000 $4.5 Million
Q2 2018 Aug 14, 2018	BUY	$101.55 - $313.9 $416,355 - $1.29 Million	4,100 New	4,100 $1.15 Million

297

21.9M

757K

370K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $3.71B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.